Myriad Genetics, Inc. (MYGN) Receives $32.40 Consensus Target Price from Brokerages

Myriad Genetics, Inc. (NASDAQ:MYGN) has been given an average rating of “Hold” by the fourteen ratings firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $34.40.

A number of brokerages have recently weighed in on MYGN. Morgan Stanley upgraded shares of Myriad Genetics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $35.00 to $55.00 in a report on Wednesday. ValuEngine upgraded shares of Myriad Genetics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, June 5th. Zacks Investment Research upgraded shares of Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $34.00 price objective for the company in a report on Friday, April 6th. TheStreet upgraded shares of Myriad Genetics from a “c+” rating to a “b” rating in a report on Monday, June 4th. Finally, BidaskClub upgraded shares of Myriad Genetics from a “buy” rating to a “strong-buy” rating in a report on Friday, May 11th.

Myriad Genetics traded up $5.01, hitting $43.04, during mid-day trading on Friday, MarketBeat reports. 3,920,797 shares of the company traded hands, compared to its average volume of 735,737. The firm has a market cap of $2.64 billion, a PE ratio of 41.67, a PEG ratio of 2.83 and a beta of 0.47. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.52 and a quick ratio of 3.16. Myriad Genetics has a one year low of $23.28 and a one year high of $44.31.



Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings data on Tuesday, May 8th. The company reported $0.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.27 by $0.04. The firm had revenue of $193.50 million during the quarter, compared to analyst estimates of $188.22 million. Myriad Genetics had a net margin of 17.67% and a return on equity of 9.52%. The business’s quarterly revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.27 EPS. research analysts anticipate that Myriad Genetics will post 1.21 earnings per share for the current year.

In other Myriad Genetics news, Director Dennis Langer sold 10,000 shares of the business’s stock in a transaction on Monday, May 21st. The shares were sold at an average price of $35.90, for a total transaction of $359,000.00. Following the transaction, the director now directly owns 49,743 shares of the company’s stock, valued at approximately $1,785,773.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Mark Christopher Capone sold 90,000 shares of the business’s stock in a transaction on Wednesday, May 30th. The shares were sold at an average price of $38.00, for a total transaction of $3,420,000.00. Following the transaction, the insider now directly owns 422,175 shares in the company, valued at $16,042,650. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 326,139 shares of company stock worth $12,684,500. 6.70% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of MYGN. Sensato Investors LLC grew its position in shares of Myriad Genetics by 1,441.8% in the 1st quarter. Sensato Investors LLC now owns 553,505 shares of the company’s stock worth $16,356,000 after buying an additional 517,605 shares during the period. Allianz Asset Management GmbH grew its position in shares of Myriad Genetics by 4,202.5% in the 4th quarter. Allianz Asset Management GmbH now owns 485,018 shares of the company’s stock worth $16,658,000 after buying an additional 473,745 shares during the period. Matarin Capital Management LLC purchased a new stake in shares of Myriad Genetics in the 1st quarter worth about $11,785,000. BlackRock Inc. grew its position in shares of Myriad Genetics by 3.2% in the 1st quarter. BlackRock Inc. now owns 10,392,278 shares of the company’s stock worth $307,091,000 after buying an additional 325,525 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec grew its position in shares of Myriad Genetics by 80.0% in the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 450,000 shares of the company’s stock worth $15,455,000 after buying an additional 200,000 shares during the period.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply